WO2015044317A3 - Staphylococcus haemolyticus inhibitors for preventing and/or treating atopic dermatitis - Google Patents

Staphylococcus haemolyticus inhibitors for preventing and/or treating atopic dermatitis Download PDF

Info

Publication number
WO2015044317A3
WO2015044317A3 PCT/EP2014/070576 EP2014070576W WO2015044317A3 WO 2015044317 A3 WO2015044317 A3 WO 2015044317A3 EP 2014070576 W EP2014070576 W EP 2014070576W WO 2015044317 A3 WO2015044317 A3 WO 2015044317A3
Authority
WO
WIPO (PCT)
Prior art keywords
atopic dermatitis
staphylococcus haemolyticus
inhibitors
preventing
treating atopic
Prior art date
Application number
PCT/EP2014/070576
Other languages
French (fr)
Other versions
WO2015044317A2 (en
Inventor
Richard Martin
Sophie SEITE
Original Assignee
L'oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by L'oreal filed Critical L'oreal
Publication of WO2015044317A2 publication Critical patent/WO2015044317A2/en
Publication of WO2015044317A3 publication Critical patent/WO2015044317A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A61K35/08—Mineral waters; Sea water
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/202—Dermatitis

Abstract

This invention relates to a dermatological composition comprising, as an active ingredient, at least one Staphylococcus haemolyticus inhibitor and the use thereof in the prevention and/or treatment of atopic dermatitis. This invention also relates to an in vitro method for prognosis and/or diagnosis of atopic dermatitis and a method for selecting a Staphylococcus haemolyticus inhibitor.
PCT/EP2014/070576 2013-09-25 2014-09-25 Staphylococcus haemolyticus inhibitors for preventing and/or treating atopic dermatitis WO2015044317A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1359248A FR3010905A1 (en) 2013-09-25 2013-09-25 STAPHYLOCOCUS HAEMOLYTICUS INHIBITORS FOR THE PREVENTION AND / OR TREATMENT OF ATOPIC DERMATITIS
FR1359248 2013-09-25

Publications (2)

Publication Number Publication Date
WO2015044317A2 WO2015044317A2 (en) 2015-04-02
WO2015044317A3 true WO2015044317A3 (en) 2015-06-04

Family

ID=50478479

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/070576 WO2015044317A2 (en) 2013-09-25 2014-09-25 Staphylococcus haemolyticus inhibitors for preventing and/or treating atopic dermatitis

Country Status (2)

Country Link
FR (1) FR3010905A1 (en)
WO (1) WO2015044317A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3038839B1 (en) * 2015-07-13 2020-04-24 Clinique Des Celestins VICHY WATER TO MODULATE BACTERIAL GROWTH
RU2613301C1 (en) * 2015-12-03 2017-03-15 Государственное бюджетное образовательное учреждение высшего профессионального образования "Тихоокеанский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ТГМУ Минздрава России) Method for prediction of infectious complications of atopic dermatitis for children in case of specific immunotherapy
KR102199063B1 (en) * 2019-09-27 2021-01-06 코스맥스 주식회사 Staphylococcus haemolyticus ST-8 strain and skin condition improving uses of thereof

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
ANNALI ITALIANI DI DERMATOLOGIA CLINICA E SPERIMENTALE, vol. 38, no. 4, 1984, pages 467 - 476, ISSN: 0365-169X *
ANONYMOUS: "Lipikar Balm AP, Lipikar by La Roche-Posay", 1 July 2014 (2014-07-01), XP055128565, Retrieved from the Internet <URL:http://www.en.laroche-posay.ca/products-treatments/Lipikar/Lipikar-Balm-AP-p3452.aspx> [retrieved on 20140714] *
BARTH J ET AL: "Sole-phototherapie - Ein wirksames behandlungsprinzip", ZEITSCHRIFT FUR DERMATOLOGIE,, vol. 184, no. 2, 1 January 1998 (1998-01-01), pages 56 - 59, XP009178938, ISSN: 0946-4115 *
BLACKWELL PUBLISHING ET AL: "Balneotherapy in dermatology", DERMATOLOGIC THERAPY, 1 January 2003 (2003-01-01), pages 132 - 140, XP055127534, Retrieved from the Internet <URL:http://www.sld.cu/galerias/pdf/sitios/rehabilitacion-bal/matzh_et_al.pdf> [retrieved on 20140708] *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1984, GARCOVICH A ET AL: "CLINICAL RESULTS WITH COMBINED MICONAZOLE-BENZOYLPEROXIDE IN THE THERAPY OF ACNE VULGARIS", XP002727160, Database accession no. PREV198580001565 *
DERMATOLOGISCHE KLINIK ET AL: "Practical management of atopic eczema", 28 May 1994 (1994-05-28), pages 1343 - 1346, XP055127543, Retrieved from the Internet <URL:http://www.sciencedirect.com/science/article/pii/S0140673694924740/pdf?md5=fbd021ee46c344d91368f037fd28757c&pid=1-s2.0-S0140673694924740-main.pdf> [retrieved on 20140708] *
HIGAKI S ET AL: "Comparative study of staphylococci from the skin of atopic dermatitis patients and from healthy subjects.", INTERNATIONAL JOURNAL OF DERMATOLOGY APR 1999, vol. 38, no. 4, April 1999 (1999-04-01), pages 265 - 269, XP002727161, ISSN: 0011-9059 *
HIGAKI S ET AL: "Susceptibility of Staphylococcus spp. to anti-infective agents during the past seven years", INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, ELSEVIER SCIENCE, AMSTERDAM, NL, vol. 24, no. 5, 1 November 2004 (2004-11-01), pages 524 - 525, XP004617425, ISSN: 0924-8579, DOI: 10.1016/J.IJANTIMICAG.2004.08.002 *
HOOVER W W ET AL: "Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative", DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASES, ELSEVIER SCIENCE PUBLISHING CO., AMSTERDAM, NL, vol. 16, no. 2, 1 February 1993 (1993-02-01), pages 111 - 118, XP023915439, ISSN: 0732-8893, [retrieved on 19930201], DOI: 10.1016/0732-8893(93)90004-Q *
IRÈNE BACLE ET AL: "Sensory analysis of four medical spa spring waters containing various mineral concentrations", INTERNATIONAL JOURNAL OF DERMATOLOGY, vol. 38, no. 10, 1 October 1999 (1999-10-01), pages 784 - 786, XP055127523, ISSN: 0011-9059, DOI: 10.1046/j.1365-4362.1999.00789.x *
SCHOPF E ET AL: "Topische Ekzembehandlung = Topical treatment of eczema", ALLERGO JOURNAL, SPRINGER MEDIZIN, DE, vol. 6, no. 2, 1 January 1997 (1997-01-01), pages 86 - 90, XP009178934, ISSN: 0941-8849 *
SOPHIE SEITE: "Thermal waters as cosmeceuticals: La Roche-Posay thermal spring water example", CLINICAL, COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 9 January 2013 (2013-01-09), pages 23, XP055128579, DOI: 10.2147/CCID.S39082 *

Also Published As

Publication number Publication date
FR3010905A1 (en) 2015-03-27
WO2015044317A2 (en) 2015-04-02

Similar Documents

Publication Publication Date Title
WO2015073587A3 (en) Synthetic membrane-receiver complexes
MX2018005829A (en) Compositions for treating the hair.
IL276153B (en) C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficiency .
WO2014144100A3 (en) Sgc stimulators
WO2016179440A3 (en) Antimicrobial therapy
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
WO2015023976A3 (en) Selective grp94 inhibitors and uses thereof
CA2900779C (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
WO2015077503A8 (en) Autotaxin inhibitor compounds
WO2015003816A3 (en) Cystobactamides
PH12016500453A1 (en) Antimicrobial compounds and methods of making and using the same
WO2015015378A3 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
WO2012158672A3 (en) Compounds for use in treatment of mucositis
WO2016094834A3 (en) A method for treating a complement mediated disorder caused by an infectious agent in a patient
EP3352755A4 (en) Novel compositions and methods for treating or preventing dermal disorders
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
WO2015026494A3 (en) Methods for treating tissue fibrosis
WO2017035176A8 (en) Method of preventing or treating obesity with an emc10 inhibitor
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
WO2015044317A3 (en) Staphylococcus haemolyticus inhibitors for preventing and/or treating atopic dermatitis
EP3327001A4 (en) Novel compound having blt inhibitory activity and composition, for preventing or treating inflammatory diseases, comprising same as active ingredient
MX2015013151A (en) Methods of treating dyskinesia and related disorders.
WO2016191695A3 (en) Treatments for obligately intracellular infections
WO2016135456A3 (en) A gm-csf negative modulator for use in treating, preventing or ameliorating aortopathy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14781108

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14781108

Country of ref document: EP

Kind code of ref document: A2